Q1 2026
Released May 7, 2026, before the open
10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-031726
Q1 2026 · 10-Q
Revenue—
Net Income-$49.12M-$49.12M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.28-$0.28 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$50,654,000N/M
Operating Cash Flow-$42,710,000N/M
Free Cash Flowderived-$42,924,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | — | $1.45M | $591.00K | $0.00 |
| Net Income | -$49.12M | -$51.89M | -$45.76M | -$39.40M |
| EPS Diluted | -$0.28 | -$0.40 | -$0.44 | -$0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR